XML 67 R56.htm IDEA: XBRL DOCUMENT
v3.23.1

License and Collaboration Agreements - Additional Information (Details) - USD ($) |  |  | 1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended |  |
--- | --- | --- | --- | --- | --- | --- | --- | ---
Mar. 31, 2023 | Mar. 29, 2021 | Feb. 28, 2023 | Jan. 31, 2023 | Dec. 31, 2022 | Aug. 31, 2020 | Oct. 31, 2019 | Sep. 30, 2019 | Mar. 31, 2023 | Mar. 31, 2022 | Jun. 30, 2023 | Dec. 31, 2021 | Jun. 30, 2022 | Feb. 28, 2022
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total revenue |  |  |  |  |  |  |  |  |  | $ 1,826,000 | $ 1,694,000 |  |  |  |
Deferred revenue, current portion | $ 6,675,000 |  |  |  | $ 8,156,000 | [1] |  |  |  | 6,675,000 |  |  |  |  |
Receivable from licensing and collaboration agreements | 10,761,000 |  |  |  | 17,079,000 | [1] |  |  |  | 10,761,000 |  |  |  |  |
Research and development |  |  |  |  |  |  |  |  |  | 92,861,000 | 107,649,000 |  |  |  |
Allowance for credit losses | 0 |  |  |  | 0 |  |  |  |  | $ 0 |  |  |  |  |
Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shares issued |  |  |  |  |  |  |  |  |  | 8,823,530 |  |  |  |  |
ASC 808 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License agreements share of co-commercialization loss as reduction to selling, general and administrative expenses |  |  |  |  |  |  |  |  |  | $ 0 | 1,200,000 |  |  |  |
Helsinn Therapeutics |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Reimbursable payment received |  |  |  |  | 15,000,000.0 |  |  |  |  |  |  |  |  |  |
Close-out plan costs subject to reimbursement |  |  |  |  |  |  |  |  |  | $ 2,400,000 |  |  |  |  |
Percentage of close-out plan costs, subject to reimbursement |  |  |  |  |  |  |  |  |  | 50.00% |  |  |  |  |
QED Therapeutics, Inc |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Close-out plan costs |  |  |  | $ 11,000,000.0 |  |  |  |  |  | $ 3,600,000 |  |  |  |  |
Receivable from licensing and collaboration agreements | 9,000,000.0 |  |  |  |  |  |  |  |  | 9,000,000.0 |  |  |  |  |
Close-out plan costs subject to reimbursement |  |  |  |  |  |  |  |  |  | 1,100,000 |  |  |  |  |
QED Therapeutics, Inc | Forecast |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Close-out plan costs |  |  |  |  |  |  |  |  |  |  |  | $ 11,000,000.0 |  |  |
QED Therapeutics, Inc | Entities Affiliated With Perceptive Life Sciences Master Fund Ltd |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrant to purchase percentage |  |  |  |  |  |  |  | 10.00% |  |  |  |  |  |  |
Nonrefundable upfront payment receivable |  |  |  |  |  |  |  | $ 10,000,000.0 |  |  |  |  |  |  |
QED Therapeutics, Inc | Maximum | Entities Affiliated With Perceptive Life Sciences Master Fund Ltd |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Future potential development and sales milestone payments yet to receive |  |  |  |  |  |  |  | $ 132,500,000 |  |  |  |  |  |  |
License and Collaboration Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Unbilled receivables | $ 10,400,000 |  |  |  | $ 16,800,000 |  |  |  |  | $ 10,400,000 |  |  |  |  |
Percentage of total unbilled receivables | 94.10% |  |  |  | 97.50% |  |  |  |  | 94.10% |  |  |  |  |
License and Collaboration Agreement | Helsinn Therapeutics |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage share of global development costs |  | 60.00% |  |  |  |  |  |  |  |  |  |  |  |  |
License and Collaboration Agreement | BMS |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment yet to be received |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 90,000,000.0 |
Upfront, regulatory and launch milestone payments yet to be received | $ 815,000,000.0 |  |  |  |  |  |  |  |  | $ 815,000,000.0 |  |  |  |  |
License and Collaboration Agreement | QED Therapeutics, Inc |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License agreement percentage share of profits and losses |  | 50.00% |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage share of global development costs |  | 40.00% |  |  |  |  |  |  |  |  |  |  |  |  |
Regulatory and sales-based milestone payments yet to be received |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 66,000,000.0
Reimbursable research and development |  |  |  |  |  |  |  |  |  | 18,800,000 |  |  |  |  |
Reimbursable commercial contracted activities |  |  |  |  |  |  |  |  |  | 12,500,000 |  |  |  |  |
License and Collaboration Agreement | QED Therapeutics, Inc | Helsinn Therapeutics | ASC 808 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development |  |  |  |  |  |  |  |  |  | 1,200,000 | 6,200,000 |  |  |  |
License and Collaboration Agreement | Navire Pharma, Inc | BMS |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments | 0 |  |  |  |  |  |  |  |  | 0 |  |  |  |  |
Initial transaction price for the license and collaboration agreement |  |  |  |  |  |  |  |  |  | 90,000,000.0 |  |  |  |  |
Allocation of transaction price for research and development |  |  |  |  |  |  |  |  |  | 19,800,000 |  |  |  |  |
Allocation of transaction price to licenses |  |  |  |  |  |  |  |  |  | 70,200,000 |  |  |  |  |
Deferred revenue | 13,600,000 |  |  |  | $ 15,300,000 |  |  |  |  | 13,600,000 |  |  |  |  |
Deferred revenue, current portion | 6,700,000 |  |  |  | 8,200,000 |  |  |  |  | 6,700,000 |  |  |  |  |
Deferred revenue, noncurrent | 6,900,000 |  |  |  | 7,100,000 |  |  |  |  | 6,900,000 |  |  |  |  |
License and Collaboration Agreement | Navire Pharma, Inc | Research and Development Expense | BMS |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total revenue |  |  |  |  |  |  |  |  |  | 1,700,000 |  |  |  |  |
License and Collaboration Agreement | Receivable from Licensing and Collaboration Agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Receivable from licensing and collaboration agreements | 10,800,000 |  |  |  | 17,100,000 |  |  |  |  | 10,800,000 |  |  |  |  |
License Agreement | Helsinn Therapeutics |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Receivable from licensing and collaboration agreements | 10,100,000 |  |  |  | $ 16,300,000 |  |  |  |  | 10,100,000 |  |  |  |  |
License Agreement | LianBio |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Nonrefundable upfront payment receivable |  |  |  |  |  |  | $ 8,000,000.0 |  |  |  |  |  |  |  |
License Agreement | LianBio | License and Services Revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total revenue |  |  |  |  |  |  |  |  |  |  |  |  | $ 8,500,000 |  |
License Agreement | Maximum | LianBio |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Future potential development and sales milestone payments yet to receive |  |  |  |  |  |  | $ 382,100,000 |  |  |  |  |  |  |  |
License Agreement | QED Therapeutics, Inc | LianBio | License and Services Revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total revenue |  |  |  |  |  |  |  |  |  | 0 | 0 |  |  |  |
License Agreement | Navire Pharma, Inc | LianBio | License and Services Revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total revenue |  |  |  |  |  |  |  |  |  | 0 | $ 0 |  |  |  |
Foundation Medicine Diagnostics Agreement | QED Therapeutics, Inc | Foundation Medicine, Inc |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Reimbursable payment received | 2,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Receivable from licensing and collaboration agreements |  |  |  | $ 5,300,000 |  |  |  |  |  |  |  |  |  |  |
Reimbursable remaining commencing installments |  |  | $ 11,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |
Reimbursable remaining due in eleven equal monthly commencing installments |  |  | $ 1,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |
Alexion License Agreements | Eidos |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront nonrefundable payment received |  |  |  |  |  |  |  |  | $ 25,000,000.0 |  |  |  |  |  |
Alexion License Agreements | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Regulatory milestone payment receivable subject to achievement of regulator milestones | 30,000,000.0 |  |  |  |  |  |  |  |  | 30,000,000.0 |  |  |  |  |
Alexion Agreements | Eidos |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total revenue |  |  |  |  |  |  |  |  | 26,700,000 |  |  |  |  |  |
Nonrefundable upfront payment receivable |  |  |  |  |  |  |  |  | $ 25,000,000.0 |  |  |  |  |  |
Alexion Agreements | Eidos | Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shares issued |  |  |  |  |  |  |  |  | 556,173 |  |  |  |  |  |
Shares issued, price per share |  |  |  |  |  |  |  |  | $ 44.95 |  |  |  |  |  |
Aggregate purchase price |  |  |  |  |  |  |  |  | $ 25,000,000.0 |  |  |  |  |  |
Excess of purchase price over the value of common stock shares | $ 1,700,000 |  |  |  |  |  |  |  |  | $ 1,700,000 |  |  |  |  |
Alexion Agreements | Eidos | Common Stock | The Nasdaq Global Select Market |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shares issued, price per share |  |  |  |  |  |  |  |  | $ 41.91 |  |  |  |  |  |
Excess of purchase price over the value of common stock shares |  |  |  |  |  |  |  |  | $ 1,700,000 |  |  |  |  |  |
[1] | The condensed consolidated balance sheet as of December 31, 2022 is derived from the audited consolidated financial statements as of that date.

X
- Definition Allocation Of Transaction Price for Research and Development. + References No definition available. + Details
Name: | bbio_AllocationOfTransactionPriceForResearchAndDevelopment
Namespace Prefix: | bbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Allocation of transaction price to licenses. + References No definition available. + Details
Name: | bbio_AllocationOfTransactionPriceToLicenses
Namespace Prefix: | bbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Close-out plan costs. + References No definition available. + Details
Name: | bbio_CloseOutPlanCosts
Namespace Prefix: | bbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Close-out plan costs subject to reimbursement. + References No definition available. + Details
Name: | bbio_CloseOutPlanCostsSubjectToReimbursement
Namespace Prefix: | bbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Excess of purchase price over the value of common stock shares. + References No definition available. + Details
Name: | bbio_ExcessOfPurchasePriceOverValueOfCommonStockShares
Namespace Prefix: | bbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | instant

X
- Definition Future potential development and sales milestone payments yet to be received. + References No definition available. + Details
Name: | bbio_FuturePotentialDevelopmentAndSalesMilestonePaymentsYetToBeReceived
Namespace Prefix: | bbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Initial transaction price for license and collaboration agreement. + References No definition available. + Details
Name: | bbio_InitialTransactionPriceForLicenseAndCollaborationAgreement
Namespace Prefix: | bbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition License agreement percentage share of profits and losses. + References No definition available. + Details
Name: | bbio_LicenseAgreementPercentageShareOfProfitsAndLosses
Namespace Prefix: | bbio_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition License agreements share of co-commercialization loss as reduction to selling, general and administrative expenses. + References No definition available. + Details
Name: | bbio_LicenseAgreementsShareOfCoCommercializationLossAsReductionToSellingGeneralAndAdministrativeExpenses
Namespace Prefix: | bbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Nonrefundable upfront payment receivable. + References No definition available. + Details
Name: | bbio_NonrefundableUpfrontPaymentReceivable
Namespace Prefix: | bbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Percentage of close-out plan costs subject to reimbursement. + References No definition available. + Details
Name: | bbio_PercentageOfCloseOutPlanCostsSubjectToReimbursement
Namespace Prefix: | bbio_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of unbilled receivables. + References No definition available. + Details
Name: | bbio_PercentageOfUnbilledReceivables
Namespace Prefix: | bbio_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Percentage share of global development costs. + References No definition available. + Details
Name: | bbio_PercentageShareOfGlobalDevelopmentCosts
Namespace Prefix: | bbio_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Potential milestone payments. + References No definition available. + Details
Name: | bbio_PotentialMilestonePayments
Namespace Prefix: | bbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Regulatory and sales-based milestone payments yet to be received. + References No definition available. + Details
Name: | bbio_RegulatoryAndSalesBasedMilestonePaymentsYetToBeReceived
Namespace Prefix: | bbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Regulatory milestone payment receivable subject to achievement of regulator milestones. + References No definition available. + Details
Name: | bbio_RegulatoryMilestonePaymentReceivableSubjectToAchievementOfRegulatorMilestones
Namespace Prefix: | bbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Reimbursable commercial contracted activities. + References No definition available. + Details
Name: | bbio_ReimbursableCommercialContractedActivities
Namespace Prefix: | bbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Reimbursable Payment Received + References No definition available. + Details
Name: | bbio_ReimbursablePaymentReceived
Namespace Prefix: | bbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Reimbursable remaining commencing installments. + References No definition available. + Details
Name: | bbio_ReimbursableRemainingCommencingInstallments
Namespace Prefix: | bbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Reimbursable remaining due in eleven equal monthly commencing installments. + References No definition available. + Details
Name: | bbio_ReimbursableRemainingDueInElevenEqualMonthlyCommencingInstallments
Namespace Prefix: | bbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Reimbursable research and development. + References No definition available. + Details
Name: | bbio_ReimbursableResearchAndDevelopment
Namespace Prefix: | bbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Stock Issued With Premium + References No definition available. + Details
Name: | bbio_StockIssuedWithPremium
Namespace Prefix: | bbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Upfront nonrefundable payment received. + References No definition available. + Details
Name: | bbio_UpfrontNonrefundablePaymentReceived
Namespace Prefix: | bbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Upfront payment yet to be received. + References No definition available. + Details
Name: | bbio_UpfrontPaymentYetToBeReceived
Namespace Prefix: | bbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Upfront, regulatory and launch milestone payments yet to be received. + References No definition available. + Details
Name: | bbio_UpfrontRegulatoryAndLaunchMilestonePaymentsYetToBeReceived
Namespace Prefix: | bbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Warrant to purchase percentage. + References No definition available. + Details
Name: | bbio_WarrantToPurchasePercentage
Namespace Prefix: | bbio_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of allowance for credit loss on accounts receivable. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 326 -SubTopic 20 -Section 50 -Paragraph 13 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section 50 -Paragraph 4 -URI https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 326 -SubTopic 20 -Section 50 -Paragraph 13 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 326 -SubTopic 20 -Section 45 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(4)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_AllowanceForDoubtfulAccountsReceivable
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)(c)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_DeferredRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_DeferredRevenueCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)(c)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_DeferredRevenueNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount to be collected within one year of the balance sheet date (or one operating cycle, if longer) from customers in accordance with the contractual provisions of long-term contracts or programs including amounts billed and unbilled as of the balance sheet date. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)(c)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_ReceivablesLongTermContractsOrPrograms
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 912 -SubTopic 730 -Section 25 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Per share or per unit amount of equity securities issued. + References No definition available. + Details
Name: | us-gaap_SharesIssuedPricePerShare
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of new stock issued during the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount received for services rendered and products shipped, but not yet billed, for non-contractual agreements due within one year or the normal operating cycle, if longer. + References No definition available. + Details
Name: | us-gaap_UnbilledReceivablesCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Details
Name: | us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201818Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=bbio_HelsinnTherapeuticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_OwnershipAxis=bbio_QEDTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=srt_ScenarioForecastMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bbio_EntitiesAffiliatedWithPerceptiveLifeSciencesMasterFundLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=bbio_LicenseAndCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=bbio_BristolMyersSquibbCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_OwnershipAxis=bbio_NavirePharmaIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BalanceSheetLocationAxis=bbio_ReceivableFromLicensingAndCollaborationAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=bbio_LicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=bbio_LianBioMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_LicenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=bbio_FoundationMedicineDiagnosticsAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=bbio_FoundationMedicineIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=bbio_AlexionLicenseAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidatedEntitiesAxis=bbio_EidosTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=bbio_AlexionAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_EntityListingsExchangeAxis=exch_XNGS
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |